ZA901261B - Dual-action tablet - Google Patents

Dual-action tablet

Info

Publication number
ZA901261B
ZA901261B ZA901261A ZA901261A ZA901261B ZA 901261 B ZA901261 B ZA 901261B ZA 901261 A ZA901261 A ZA 901261A ZA 901261 A ZA901261 A ZA 901261A ZA 901261 B ZA901261 B ZA 901261B
Authority
ZA
South Africa
Prior art keywords
tablet
active ingredient
dual
dose
action
Prior art date
Application number
ZA901261A
Other languages
English (en)
Inventor
Richard John Dansereau
John Dansereau Richard
Michael John Kane
John Kane Michael
Original Assignee
Norwich Eaton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norwich Eaton Pharma filed Critical Norwich Eaton Pharma
Publication of ZA901261B publication Critical patent/ZA901261B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA901261A 1989-02-21 1990-02-20 Dual-action tablet ZA901261B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/314,672 US5032406A (en) 1989-02-21 1989-02-21 Dual-action tablet

Publications (1)

Publication Number Publication Date
ZA901261B true ZA901261B (en) 1990-11-28

Family

ID=23220946

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA901261A ZA901261B (en) 1989-02-21 1990-02-20 Dual-action tablet

Country Status (15)

Country Link
US (1) US5032406A (fr)
EP (1) EP0384514B1 (fr)
JP (1) JP2895146B2 (fr)
KR (1) KR0173115B1 (fr)
AT (1) ATE97571T1 (fr)
AU (1) AU632793B2 (fr)
CA (1) CA2010037C (fr)
DE (1) DE69004708T2 (fr)
DK (1) DK0384514T3 (fr)
ES (1) ES2060923T3 (fr)
IE (1) IE63311B1 (fr)
IL (1) IL93424A (fr)
NZ (1) NZ232604A (fr)
PH (1) PH27331A (fr)
ZA (1) ZA901261B (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200197A (en) * 1989-11-16 1993-04-06 Alza Corporation Contraceptive pill
IE64128B1 (en) * 1990-02-26 1995-07-12 Byrne Rynne Holdings Ltd A pharmaceutical composition
US5284659A (en) * 1990-03-30 1994-02-08 Cherukuri Subraman R Encapsulated flavor with bioadhesive character in pressed mints and confections
US5158728A (en) * 1991-04-12 1992-10-27 Elizabeth-Hata International, Inc. Multi-layer medicinal tablet forming machine and method for using the same
FI93924C (fi) * 1991-09-17 1995-06-26 Martti Lauri Antero Marvola Menetelmä säädellysti lääkeainetta vapauttavan valmisteen valmistamiseksi
DE69222006T2 (de) * 1991-10-30 1998-01-22 Glaxo Group Ltd Mehrschichtzusammensetzungen enthaltend Histamin- oder Serotonin- Antagonisten
DK0550108T3 (da) * 1991-12-30 1999-01-04 Akzo Nobel Nv Thyreoaktiv sammensætning med langvarig frigivelse
WO1993019741A1 (fr) * 1992-03-31 1993-10-14 Benzon Pharma A/S Formulation pharmaceutique
US5656296A (en) * 1992-04-29 1997-08-12 Warner-Lambert Company Dual control sustained release drug delivery systems and methods for preparing same
IT1260505B (it) † 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
US5422122A (en) * 1992-08-04 1995-06-06 Eurand America, Incorporated Controlled release potassium chloride tablet
IT1264696B1 (it) * 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US5399358A (en) * 1993-11-12 1995-03-21 Edward Mendell Co., Inc. Sustained release formulations for 24 hour release of metroprolol
US5399359A (en) * 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
US5399362A (en) * 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
US5595759A (en) * 1994-11-10 1997-01-21 Alza Corporation Process for providing therapeutic composition
CN1183044A (zh) * 1995-04-03 1998-05-27 中外制药株式会社 含有硫糖铝的制剂组合物
US5759574A (en) * 1995-05-15 1998-06-02 Bothe; Steven T. Tel-tale-tablets
IT1276689B1 (it) * 1995-06-09 1997-11-03 Applied Pharma Res Forma farmaceutica solida ad uso orale
US5807579A (en) * 1995-11-16 1998-09-15 F.H. Faulding & Co. Limited Pseudoephedrine combination pharmaceutical compositions
WO1997026865A1 (fr) * 1996-01-29 1997-07-31 Edward Mendell Co., Inc. Excipient a liberation prolongee
KR19980077329A (ko) * 1997-04-18 1998-11-16 이범진 이중층 약물 함유 제어방출성 제제
US6143309A (en) 1998-03-12 2000-11-07 Archimica (Florida), Inc. Delivery of hydroxy carboxylic acids
US6372254B1 (en) * 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
US6387381B2 (en) 1998-09-24 2002-05-14 Ez-Med Company Semi-moist oral delivery system
US6773716B2 (en) * 1999-04-06 2004-08-10 Wm. Wrigley Jr. Company Over-coated chewing gum formulations
IT1313590B1 (it) * 1999-08-03 2002-09-09 Formenti Farmaceutici Spa Composizioni a rilascio controllato di acido acetilsalicilico.
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US6372252B1 (en) * 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
EA008224B1 (ru) * 2001-03-13 2007-04-27 Пенвест Фармасьютикалз Ко. Хронотерапевтические дозированные формы
JP2002326961A (ja) * 2001-04-27 2002-11-15 Taiyo Kagaku Co Ltd 打錠用滑沢剤
US20030012820A1 (en) * 2001-06-12 2003-01-16 Upadhyay Ajay Hasmukhlal Compressible guaifenesin compositions, method for making same and method for making compressed guaifenesin dosage forms therefrom
US6837696B2 (en) * 2001-09-28 2005-01-04 Mcneil-Ppc, Inc. Apparatus for manufacturing dosage forms
CA2447984A1 (fr) * 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Formes dosifiees presentant un noyau interne et une couche externe de formes differentes
CA2481091A1 (fr) * 2002-04-05 2003-10-23 Penwest Pharmaceuticals Co. Formulations de metoprolol a liberation prolongee
CN1655766B (zh) * 2002-04-15 2012-05-30 利洁时有限责任公司 愈创甘油醚组合药物的持续释放
DE10224108A1 (de) * 2002-05-29 2004-01-29 Grünenthal GmbH 1-Dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol enthaltendes Arzneimiitel mit verzögerter Wirkstofffreisetzung
US7632521B2 (en) * 2003-07-15 2009-12-15 Eurand, Inc. Controlled release potassium chloride tablets
US20050118267A1 (en) * 2003-09-19 2005-06-02 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
EA200600598A1 (ru) * 2003-09-19 2006-08-25 Пенвест Фармасьютикалз Ко. Лекарственные формы замедленного высвобождения
MY147202A (en) * 2003-11-26 2012-11-14 Novartis Ag Compositions comprising organic compounds
CN1327838C (zh) * 2004-07-08 2007-07-25 北京科信必成医药科技发展有限公司 维生素c口腔崩解片及其制备方法
CN1297263C (zh) * 2004-10-25 2007-01-31 北京科信必成医药科技发展有限公司 葡萄糖酸钙口腔崩解片及其制备工艺
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
US20060257473A1 (en) * 2005-05-11 2006-11-16 Porranee Puranajoti Extended release tablet
US8765178B2 (en) 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
US20090202633A1 (en) * 2008-01-03 2009-08-13 Siva Ramakrishna Velaga Extended release formulations of guaifenesin
AU2009289464B2 (en) * 2008-09-04 2015-12-10 Farnam Companies, Inc. Chewable sustained release formulations
TR201001903A2 (tr) 2010-03-12 2011-04-21 Ali̇ Rai̇f İlaç Sanayi̇ Ve Ti̇caret A.Ş. Uzatılmış salımlı tiyokolşiklozit tablet.
GB201506755D0 (en) 2015-04-21 2015-06-03 Reckitt Benckiser Llc Novel pharmaceutical formulation
CA2936741C (fr) 2014-10-31 2018-11-06 Purdue Pharma Methodes et compositions destinees au traitement du trouble de deficit d'attention
KR101684797B1 (ko) * 2015-08-27 2016-12-08 오철환 개폐구조를 갖는 글루건
US11278506B2 (en) 2015-10-09 2022-03-22 Rb Health (Us) Llc Pharmaceutical formulation
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
CN112472679A (zh) * 2020-12-02 2021-03-12 上海汉维生物医药科技有限公司 双释放片及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE556141A (fr) * 1956-03-27
US2951792A (en) * 1959-11-18 1960-09-06 Smith Kline French Lab Sustained release pharmaceutical tablets
US3388041A (en) * 1964-01-27 1968-06-11 Richardson Merrell Inc High dosage sustained release tablet
FR1545612A (fr) * 1967-06-15 1968-11-15 Dausse Lab Procédé de fabrication de comprimés
GB1276089A (en) * 1968-08-23 1972-06-01 Pfizer Ltd Pharmaceutical preparations
US3558768A (en) * 1969-12-19 1971-01-26 Sterling Drug Inc Sustained release pharmaceutical compositions
SE418247B (sv) * 1975-11-17 1981-05-18 Haessle Ab Sett att framstella kroppar med reglerad frigoring av en aktiv komponent
DE3113901A1 (de) * 1981-04-07 1982-10-28 Basf Ag, 6700 Ludwigshafen Wirkstoffzubereitung zur oralen applikation
US4552899A (en) * 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
IT1191674B (it) * 1986-03-07 1988-03-23 Eurand Spa Formulazioni per la preparazione di farmaci a rilascio prolungato adatte alla somministrazione per via orale
US4756911A (en) * 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
DE3720757A1 (de) * 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette

Also Published As

Publication number Publication date
US5032406A (en) 1991-07-16
EP0384514A2 (fr) 1990-08-29
IL93424A0 (en) 1990-11-29
ATE97571T1 (de) 1993-12-15
EP0384514B1 (fr) 1993-11-24
DE69004708D1 (de) 1994-01-05
IE900629L (en) 1990-08-21
KR0173115B1 (ko) 1999-02-01
NZ232604A (en) 1992-10-28
KR900012606A (ko) 1990-09-01
DE69004708T2 (de) 1994-03-24
JP2895146B2 (ja) 1999-05-24
EP0384514A3 (fr) 1991-04-03
IL93424A (en) 1994-02-27
PH27331A (en) 1993-06-08
ES2060923T3 (es) 1994-12-01
AU632793B2 (en) 1993-01-14
AU4997090A (en) 1990-08-30
IE63311B1 (en) 1995-04-05
DK0384514T3 (da) 1994-02-07
CA2010037A1 (fr) 1990-08-21
JPH03200724A (ja) 1991-09-02
CA2010037C (fr) 1995-10-31

Similar Documents

Publication Publication Date Title
IL93424A0 (en) Dual-action tablet
EP1382331B1 (fr) Comprimé pharmaceutique caractérisé par une augmentation de volume en cas de contact avec des fluides biologiques
US4695591A (en) Controlled release dosage forms comprising hydroxypropylmethylcellulose
EP0386801B1 (fr) Composition pharmaceutique à libération lente
AU1351788A (en) Slow-release pharmaceutical agent
HU228269B1 (en) Hydrophilic/lipophilic polymeric matrix dosage formulation
PL304860A1 (en) Drug of prolonged active substance release containing a tramadol salt
HU9300768D0 (en) Veramply tablet of controlled dissolution
MY136318A (en) Sustained-release tablet composition
CA2231195A1 (fr) Matrice a liberation prolongee pour medicaments insolubles en doses elevees
CA2377299A1 (fr) Compositions pharmaceutiques orales a liberation regulee a base de mesalazine
CA2171844A1 (fr) Formulations de liberation prolongee de metoprolol pendant 24 heures
HK1039891A1 (en) Improved fast disintegrating tablet
AU2793989A (en) Method for preparing a solid sustained release form of a functionally active composition and the dosage form so obtained
WO2002087547A1 (fr) Procede ameliore pour preparer une association a dose fixe de quatre medicaments antituberculeux
EP0126453B1 (fr) Comprimé avec libération contrôlée
WO1996016638A1 (fr) Administration de medicament a liberation prolongee comprenant une gomme hydrocolloide en poudre obtenue a partir de spermatophytes
CA2006184A1 (fr) Compose a liberation prolongee a base de trimebutine et procede de preparation
KR20180101307A (ko) 티아넵틴 또는 이의 약제학적으로 허용되는 염을 포함하는 경구투여용 서방성 정제
US20050271718A1 (en) Sustained release propafenone hydrochloride capsules
ATE90555T1 (de) Scleroglucan und wirkstoff enthaltende pharmazeutische tabletten und kapselgranulate.
ZA200309212B (en) An improved process for preparation of four-drug anti-tubercular fixed dose combination.